The clinical oncology next-generation sequencing market share is expected to reach a value of US$ 449.4 million by 2022. Owing to the increasing application of next-generation sequencing (NGS) in clinical oncology for more effective, individualised cancer treatment, the market is anticipated to grow at an astounding 16.3% CAGR from 2022 to 2029, when it will …